Agreements reached under this partnership
Capital and Business Alliance- 1
The companies will consider the potential expansion of medical digital health services for migraine and ALS (amyotrophic lateral sclerosis) to pharmaceutical companies and other parties.
- 2
Alfresa will use its network of medical institutions, pharmaceutical companies and other parties to support the implementation and use of the digital health services developed and provided by eMind.
- 3
The companies will consider the potential joint development and commercialization of new digital therapeutics and digital health services.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
This indicates whether the companies will do more than work together, such as holding each other’s shares or seconding personnel (capital and business alliance).
The impact of this transaction on performance for the current fiscal year is expected to be immaterial, but the Company believes it will contribute to enhancing the corporate value of the Group over the medium to long term.
| Item | Details |
|---|---|
| Name of alliance partner | eMind |
| Alliance partner's business activities | Information provision services, Provision of information systems services, Planning, design, management and operation of information systems, Design, development, sale and maintenance of computer software, Marketing research and consulting services relating to information systems, Management consulting services |
| Alliance partner's location | Chiyoda-ku, Tokyo |
| Alliance partner's capital | ¥106 million |
| Type of alliance | Capital and Business Alliance |
| Details of the alliance | The companies will consider the potential expansion of medical digital health services for migraine and ALS (amyotrophic lateral sclerosis) to pharmaceutical companies and other parties., Alfresa will use its network of medical institutions, pharmaceutical companies and other parties to support the implementation and use of the digital health services developed and provided by eMind., The companies will consider the potential joint development and commercialization of new digital therapeutics and digital health services. |
| Acquisition price | Approximately ¥350 million |
| Contract Date | 12 June 2026 |
| Impact on Business Performance | The impact of this transaction on performance for the current fiscal year is expected to be immaterial, but the Company believes it will contribute to enhancing the corporate value of the Group over the medium to long term. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.By combining Alfresa's network of medical institutions and pharmaceutical companies with eMind's digital technology, the companies aim to commercialize digital health services and promote their implementation in healthcare settings, thereby contributing to improvements in the quality of healthcare and patients' QOL.